Date set for National Institute for Health and Clinical Excellence dementia drugs judicial review

    The National Institute for Health and Clinical Excellence will face a judicial review into its decision to restrict access on the NHS to three dementia drugs at the High Court from 25 June.

    The healthcare advisory body had ruled that three drugs, Aricept, Exelon and Reminyl, should no longer be available for people with mild or severe dementia, but drugs companies Eisai and Pfizer successfully persuaded the court to grant a review, the first into a Nice decision.

    The hearing has been scheduled for four days.

    Previous articles:

    Alzheimer’s Society takes drugs storm to High Court

    New guidance out as drug ruling bites

    Alzheimer’s drug appeal rejected

    More from Community Care

    Comments are closed.